Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers

Ilya Pharma

Status and phase: Terminated; Phase 2

Conditions: Wound Healing Disorder; Wound Healing Disturbance of; Diabetic Foot Ulcer Mixed; Wound Heal; Diabetic Foot Ulcer; Wound Healing Delayed

Treatments: Biological: ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2; Biological: Placebo; Biological: ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05608187

2021-000563-69 (EudraCT Number)

IP-CT-003

Details and patient eligibility

About

A randomized, double-blind, placebo-controlled, parallel, exploratory phase 2a study to evaluate safety and biologic efficacy on wound healing of ILP100-Topical in subjects with diabetic foot ulcers during 26 weeks with a 5-year long-term follow-up period. A total of 30 subjects will be randomized to low dose of ILP100-Topical (ILP100Lo), high dose of ILP100-Topical (ILP100Hi) or Placebo according to a 1:1:1 randomization schedule.

The study will consist of a 3-weeks Screening and Run-in Phase, followed by a 5-week Treatment Phase starting from Baseline and an Assessment Phase from Week 5 to Week 26. Thereafter, the subjects will be followed yearly during 5 years in a Long-Term Safety Follow-up Phase.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent

• Males and females aged ≥18 years

• Diagnosis of diabetes mellitus type 1 or 2

• HbA1c ≤ 86 mmol/mol (≤ 10%) at Screening

• Subjects with at least one first time or recurrent full thickness ulcer (at or below the ankle) which fulfils all of the following criteria at Screening and at the time of Baseline:

  1. A non-interdigital wound
  2. Accessible for administration of IMP, wound study assessments and procedures
  3. Persistence of the wound for at least 6 weeks at Baseline
  4. Assessed by the investigator to be of non-venous etiology.
  5. Minimum full skin ulcer without undermining, with no exposed muscle, tendon or bone
  6. A wound area of 1.0 - 5.0 cm^2 after sharp or mechanical debridement at Screening
  7. During the 2-weeks between start of Run-in Phase and Baseline the wound size must not decrease by more than 30% or increase by more than 25%, which correspond to wound areas of 0.7 - 6.3 cm^2, or at Screening expected by the Investigator to have a high probability for wound size changes within this range during this period.

• Toe pressure ≥20 mm Hg

• Expected to comply with the study procedures

Exclusion criteria

• Infected index wound with clinical signs of inflammation at Screening or Baseline.
• The index wound determined as heavily exuding defined as requiring more than 1 dressing change per day or requiring use of super absorbent dressing
• Wound duration longer than 2 years
• Active Charcot deformity of the study foot
• Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2
• Hemoglobin concentration <100 g/L at Baseline
• Planned or ongoing treatment with corticosteroids to an equivalent dose of prednisolone >10 mg per day or other immunosuppressive therapy, or such treatment within 4 weeks prior to Baseline
• Has any major surgery or hospitalization planned up to Week 26
• Has changed a treatment for diabetes during the last 3 weeks before Baseline. Dose change is allowed
• Ongoing treatment with dipeptidyl peptidase 4 (DPP-4) inhibitors
• Revascularization procedure in the index wound leg planned or undertaken within 8 weeks before Screening, or under investigation
• Current smokers
• Participation in other clinical studies or having received any investigational treatment within 1 month or at the earliest five times the half-life prior to Screening
• Has any disease conditions, including ulcerative dermatological disorders and vasculitis, or comorbidities which is expected to prevent the subject from participating in the study or confounding the evaluation of the safety profile and effect on wound healing of ILP100
• Pregnant or lactating woman
• Male subjects not willing to use a condom and refrain from donating sperm
• Female subjects of childbearing potential unless they use a contraceptive method with a failure rate of < 1% to prevent pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1 participants in 3 patient groups, including a placebo group

ILP100Lo

Experimental group

Description:

During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Lo (ILP100-Topical, 5x10\^7 colony forming units (CFU)/cm\^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.

Treatment:

Biological: ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2

ILP100Hi

Experimental group

Description:

During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Hi (ILP100-Topical, 1x10\^9 CFU/cm\^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.

Treatment:

Biological: ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2

Placebo

Placebo Comparator group

Description:

During the Treatment Phase, subjects will continue on standard of care according to the protocol and Placebo (ILP100 dilution buffer mixed with the activation peptide SppIP) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.

Treatment:

Biological: Placebo